PDCD1 and renal carcinoma: Considering the beneficial impact on the patient’s outcome, the immunotherapies based on anti-PD-1/PD-L1 mAbs were approved in other malignancies, including non-small-cell lung cancer (NSCLC), renal cancer, and hepatocellular carcinoma.